Soltis Investment Advisors LLC Buys Shares of 2,194 GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Soltis Investment Advisors LLC purchased a new position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 2,194 shares of the company’s stock, valued at approximately $206,000.

A number of other institutional investors have also recently made changes to their positions in the stock. LGT Financial Advisors LLC grew its position in GE HealthCare Technologies by 1,673.3% in the third quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after acquiring an additional 251 shares in the last quarter. Fred Alger Management LLC purchased a new position in shares of GE HealthCare Technologies in the 2nd quarter worth about $26,000. Capital Performance Advisors LLP purchased a new position in shares of GE HealthCare Technologies in the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC bought a new position in shares of GE HealthCare Technologies during the 3rd quarter valued at about $26,000. Finally, Elkhorn Partners Limited Partnership purchased a new position in shares of GE HealthCare Technologies during the 2nd quarter valued at about $31,000. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Stock Down 1.4 %

Shares of NASDAQ:GEHC opened at $81.63 on Friday. The stock’s 50-day moving average is $86.04 and its 200 day moving average is $83.70. The company has a market cap of $37.29 billion, a PE ratio of 22.43, a P/E/G ratio of 2.96 and a beta of 1.07. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98. GE HealthCare Technologies Inc. has a 1 year low of $71.31 and a 1 year high of $94.55.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.08. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The firm had revenue of $4.86 billion for the quarter, compared to analysts’ expectations of $4.87 billion. During the same period in the previous year, the firm earned $0.99 earnings per share. The business’s revenue was up .9% compared to the same quarter last year. Sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 EPS for the current year.

GE HealthCare Technologies Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be given a $0.035 dividend. This represents a $0.14 annualized dividend and a dividend yield of 0.17%. This is a boost from GE HealthCare Technologies’s previous quarterly dividend of $0.03. The ex-dividend date is Tuesday, January 14th. GE HealthCare Technologies’s dividend payout ratio (DPR) is currently 3.30%.

Analyst Ratings Changes

A number of brokerages have commented on GEHC. UBS Group cut shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and reduced their price target for the company from $84.00 to $74.00 in a research report on Thursday, September 26th. BTIG Research raised shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a report on Wednesday, September 18th. JPMorgan Chase & Co. initiated coverage on shares of GE HealthCare Technologies in a research report on Monday, September 9th. They issued a “neutral” rating and a $90.00 target price on the stock. Wells Fargo & Company upped their price target on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a research report on Thursday, October 31st. Finally, Evercore ISI lifted their price objective on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, GE HealthCare Technologies currently has an average rating of “Moderate Buy” and an average target price of $95.46.

Insider Activity

In other news, CEO Roland Rott sold 3,577 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total value of $309,338.96. Following the completion of the transaction, the chief executive officer now owns 24,298 shares of the company’s stock, valued at approximately $2,101,291.04. This represents a 12.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.